AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24603844 — intervention group
Group type: EXPERIMENTAL
Intervention: Using 4 weekdays
Number of subjects: 57
Study 24603844 — intervention group
Group type: EXPERIMENTAL
Intervention: Using 5 weekdays
Number of subjects: 57
Study 24603844 — intervention group
Group type: EXPERIMENTAL
Intervention: Excluding days with < 8 h wearing time
Number of subjects: 57
Study 24603844 — intervention group
Group type: EXPERIMENTAL
Intervention: Considering the difference in daylight time (DT) as a covariate
Number of subjects: 57
Study 21982055 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 12
Study 21982055 — intervention group
Group type: EXPERIMENTAL
Intervention: 755 nm laser therapy
Number of subjects: 12
Study 21982055 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidermal abrasion
Number of subjects: 12
Study 21982055 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 12
Study 21982055 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus cream
Number of subjects: 12
Study 21982055 — intervention group
Group type: EXPERIMENTAL
Intervention: Local steroids
Number of subjects: 12
Study 21982055 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream
Number of subjects: 12
Study 20738062 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led community care program (Network Collaborative Action Plan - N-CAP)
Number of subjects: 91
Study 20738062 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical controls)
Number of subjects: 91
Study 18477082 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 78
Study 18477082 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 78
Study 15909439 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical negative pressure (TNP)
Number of subjects: 54
Study 15909439 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (moist gauze)
Number of subjects: 54
Study 12878948 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (1 cycle of 5 minutes of ischemia/5 minutes of reperfusion) in group III (surgery on the beating heart)
Number of subjects: 120
Study 12878948 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning in vitro (5 minutes of ischemia and 5 minutes of reoxygenation before long ischemic insult)
Number of subjects: 120
Study 12878948 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ischemic preconditioning) in vitro
Number of subjects: 120
Study 12878948 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscles obtained 10 minutes after initiation of cardiopulmonary bypass
Number of subjects: 120
Study 10537958 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intrathecal baclofen infusion via a subcutaneously implanted programmable pump (SynchroMed, Medtronic)
Number of subjects: 18
Study 10537958 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intrathecal baclofen infusion
Number of subjects: 18
Study 8679058 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 Health Survey
Number of subjects: 532
Study 8679058 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 Mental Health Scale
Number of subjects: 532
Study 8679058 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 Mental Component Summary
Number of subjects: 532
Study 1830108 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg twice daily
Number of subjects: 32
Study 1830108 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 5.0 mg once daily
Number of subjects: 32
Study 3978012 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine i.v. to maintain systolic arterial pressure at or above 100 mm Hg (Group A)
Number of subjects: 38
Study 3978012 — intervention group
Group type: COMPARATOR
Intervention: No ephedrine (Group B)
Number of subjects: 38
Study 31309868 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch-supplemented medium (RSM)
Number of subjects: 10
Study 30048648 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity low volume (HILV) exercise
Number of subjects: 23
Study 30048648 — intervention group
Group type: COMPARATOR
Intervention: Moderate continuous aerobic training (MCT)
Number of subjects: 23
Study 27892423 — intervention group
Group type: EXPERIMENTAL
Intervention: mobile telemonitoring guided cardiac rehabilitation (mCR) - personalized home-based programme
Number of subjects: 238
Study 27892423 — intervention group
Group type: COMPARATOR
Intervention: no advice or coaching (Control)
Number of subjects: 238
Study 24837444 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 407
Study 24837444 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 407
Study 24837444 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine plus Gabapentin
Number of subjects: 407
Study 24837444 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine vs. Pregabalin
Number of subjects: 407
Study 24837444 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine vs. Duloxetine plus Gabapentin
Number of subjects: 407
Study 24837444 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin vs. Duloxetine and Duloxetine plus Gabapentin
Number of subjects: 407
Study 24837444 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine plus Gabapentin vs. Pregabalin
Number of subjects: 407
Study 24837444 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight change among treatment groups
Number of subjects: 407
Study 22592504 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's wort (SJW) 900-1500 mg
Number of subjects: 124
Study 22592504 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50-100 mg
Number of subjects: 124
Study 22592504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 19891698 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU)
Number of subjects: 38
Study 19891698 — intervention group
Group type: COMPARATOR
Intervention: Subdermal testosterone implants (TI)
Number of subjects: 38
Study 22884063 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/d oral progesterone
Number of subjects: 80
Study 22884063 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/d oral progesterone
Number of subjects: 80
Study 22884063 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/d oral progesterone
Number of subjects: 80
Study 22884063 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/d oral progesterone
Number of subjects: 80
Study 15984008 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (100mg)
Number of subjects: 0
Study 15984008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12822089 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy (group B)
Number of subjects: 118
Study 12822089 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnification endoscopy (group C)
Number of subjects: 118
Study 12822089 — intervention group
Group type: COMPARATOR
Intervention: Conventional endoscopy (group A)
Number of subjects: 118
Study 12822089 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted biopsies after intravital staining
Number of subjects: 118
Study 9801526 — intervention group
Group type: EXPERIMENTAL
Intervention: Recorded, preferred music played during bathing episodes
Number of subjects: 18
Study 9801526 — intervention group
Group type: COMPARATOR
Intervention: Control (no music) condition
Number of subjects: 18
Study 8549849 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet
Number of subjects: 0
Study 8549849 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (good compliance)
Number of subjects: 0
Study 2672062 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy at high intensity (2000 lux)
Number of subjects: 16
Study 2672062 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy at low intensity (300 lux)
Number of subjects: 16
Study 2672062 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 16
Study 805354 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendigon
Number of subjects: 28
Study 31808295 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 802
Study 31808295 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 802
Study 30859660 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric (2,100 mg powdered rhizome of turmeric daily)
Number of subjects: 80
Study 30859660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 28683750 — intervention group
Group type: EXPERIMENTAL
Intervention: mRDTs intervention arm
Number of subjects: 2400
Study 28683750 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 2400
Study 25120022 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5x ED95 rocuronium bromide
Number of subjects: 100
Study 25120022 — intervention group
Group type: EXPERIMENTAL
Intervention: 1x ED95 rocuronium bromide
Number of subjects: 100
Study 25120022 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5x ED95 rocuronium bromide
Number of subjects: 100
Study 25120022 — intervention group
Group type: EXPERIMENTAL
Intervention: 2x ED95 rocuronium bromide
Number of subjects: 100
Study 25120022 — intervention group
Group type: COMPARATOR
Intervention: No rocuronium bromide (Control group)
Number of subjects: 100
Study 22961992 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 3
Study 22961992 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction strategy
Number of subjects: 3
Study 22961992 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous strategies
Number of subjects: 3
Study 21042901 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIPA™
Number of subjects: 101
Study 21042901 — intervention group
Group type: COMPARATOR
Intervention: LMA‐ProSeal™
Number of subjects: 101
Study 21042901 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIPA™ and LMA‐ProSeal™
Number of subjects: 101
Study 18793923 — intervention group
Group type: EXPERIMENTAL
Intervention: epoxy resin-based sealer (plus gutta-percha)
Number of subjects: 22
Study 18793923 — intervention group
Group type: COMPARATOR
Intervention: untreated canal
Number of subjects: 22
Study 18793923 — intervention group
Group type: EXPERIMENTAL
Intervention: epoxy resin infiltration
Number of subjects: 22
Study 16582864 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid (2.2 g, single dose 30 min before surgery)
Number of subjects: 698
Study 16582864 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (2 g, single dose 30 min before surgery)
Number of subjects: 698
Study 12837854 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-346086 (10 mg/kg/day) for 2 weeks
Number of subjects: 0
Study 12837854 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-346086 (single oral dose of 100 mg)
Number of subjects: 0
Study 12837854 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-346086 (single oral dose of 1.3 mg/kg)
Number of subjects: 0
Study 12837854 — intervention group
Group type: COMPARATOR
Intervention: CP-346086 (30 mg/day for 2 weeks)
Number of subjects: 0
Study 10755457 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula milk supplemented with 0.35% DHA
Number of subjects: 56
Study 10755457 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula milk supplemented with 0.36% DHA and 0.72% arachidonic acid (AA)
Number of subjects: 56
Study 10755457 — intervention group
Group type: COMPARATOR
Intervention: Control formula (no DHA or AA)
Number of subjects: 56
Study 8621785 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (7 grams x 3/day)
Number of subjects: 27
Study 8621785 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder
Number of subjects: 27
Study 1413587 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 78
Study 1413587 — intervention group
Group type: COMPARATOR
Intervention: UHF therapy
Number of subjects: 78
Study 3890140 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (not specified dosage or duration)
Number of subjects: 8
Study 3890140 — intervention group
Group type: COMPARATOR
Intervention: GIP infusion without atropine
Number of subjects: 8
Study 31915366 — intervention group
Group type: EXPERIMENTAL
Intervention: venetoclax + hypomethylating agent
Number of subjects: 0
Study 31915366 — intervention group
Group type: EXPERIMENTAL
Intervention: glasdegib
Number of subjects: 0
Study 31915366 — intervention group
Group type: EXPERIMENTAL
Intervention: ivosidenib
Number of subjects: 0
Study 31915366 — intervention group
Group type: EXPERIMENTAL
Intervention: midostaurin
Number of subjects: 0
Study 31915366 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX-351
Number of subjects: 0
Study 31915366 — intervention group
Group type: EXPERIMENTAL
Intervention: gemtuzumab ozogamicin (GO)
Number of subjects: 0
Study 29694236 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted teaching
Number of subjects: 28
Study 29694236 — intervention group
Group type: COMPARATOR
Intervention: Routine teaching
Number of subjects: 28
Study 26117584 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-defined attractive body parts exposure
Number of subjects: 22
Study 26117584 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-defined unattractive body parts exposure
Number of subjects: 22
Study 24952868 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal heart rate pattern 3 (nondipping)
Number of subjects: 492
Study 24952868 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal heart rate patterns 2 and 3
Number of subjects: 492
Study 23106927 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 129
Study 23106927 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine
Number of subjects: 129
Study 20204353 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological evaluation of bone fragments obtained during radiofrequency ablation (RFA)
Number of subjects: 39
Study 18315507 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 300 mg three times a day for 6 months
Number of subjects: 33
Study 18315507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 15966876 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser treatment with wavelengths of 635 and 830 nm
Number of subjects: 17
Study 15966876 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 17
Study 12198695 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal perfusion of lipids at 1 kcal/min
Number of subjects: 30
Study 12198695 — intervention group
Group type: COMPARATOR
Intervention: Duodenal perfusion of lipids at 0 kcal/min (saline)
Number of subjects: 30
Study 12198695 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal perfusion of lipids at 0.5 kcal/min
Number of subjects: 30
Study 12198695 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas plus lipids challenge test
Number of subjects: 30
Study 10202870 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 38
Study 10202870 — intervention group
Group type: COMPARATOR
Intervention: IVF
Number of subjects: 38
Study 10202870 — intervention group
Group type: COMPARATOR
Intervention: IVF vs ICSI
Number of subjects: 38
Study 7758260 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (60 U at 0 min)
Number of subjects: 17
Study 7758260 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (120 U at 0 min)
Number of subjects: 17
Study 7758260 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (60 U at 0 and +20 min)
Number of subjects: 17
Study 7758260 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (120 U at +20 min)
Number of subjects: 17
Study 7758260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 7758260 — intervention group
Group type: EXPERIMENTAL
Intervention: Post‐prandial intravenous insulin
Number of subjects: 17
Study 2083922 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS 205-930 (20 mg infused intravenously)
Number of subjects: 12
Study 2083922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 227180 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 gm. l‐tryptophan
Number of subjects: 18
Study 227180 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 gms. l‐tryptophan
Number of subjects: 18
Study 227180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30153085 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass azithromycin distribution
Number of subjects: 1005
Study 28504988 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural catheter placement at L4-5 interspace
Number of subjects: 148
Study 28504988 — intervention group
Group type: COMPARATOR
Intervention: Epidural catheter placement at L1-2 interspace
Number of subjects: 148
Study 26895846 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric care (CGC)
Number of subjects: 397
Study 25225008 — intervention group
Group type: EXPERIMENTAL
Intervention: Creighton Model FertilityCare System (CrMS) instruction
Number of subjects: 143
Study 25225008 — intervention group
Group type: COMPARATOR
Intervention: Control group advice to have intercourse 2‐3 times per week
Number of subjects: 143
Study 21805606 — intervention group
Group type: EXPERIMENTAL
Intervention: Nobori biolimus A9-eluting stent
Number of subjects: 335
Study 21805606 — intervention group
Group type: COMPARATOR
Intervention: Cypher sirolimus-eluting stent
Number of subjects: 335
Study 19386792 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous PTH administered subcutaneously to male Sprague-Dawley rats
Number of subjects: 0
Study 17244215 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% once daily
Number of subjects: 65
Study 17244215 — intervention group
Group type: COMPARATOR
Intervention: Timolol‐dorzolamide combination twice daily
Number of subjects: 65
Study 15821205 — intervention group
Group type: EXPERIMENTAL
Intervention: IV clindamycin
Number of subjects: 100
Study 15821205 — intervention group
Group type: COMPARATOR
Intervention: IV ampicillin/sulbactam (normal dose)
Number of subjects: 100
Study 15821205 — intervention group
Group type: COMPARATOR
Intervention: IV ampicillin/sulbactam (half dose)
Number of subjects: 100
Study 15821205 — intervention group
Group type: COMPARATOR
Intervention: IV panipenem/betamiprom
Number of subjects: 100
Study 11997277 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 897
Study 11997277 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 897
Study 9219402 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 200 mg daily for 5 days
Number of subjects: 154
Study 9219402 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V 250 mg four times a day for 5 days
Number of subjects: 154
Study 9219402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 7715474 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/day percutaneous 17 beta‐oestradiol (E2) for 36 months
Number of subjects: 68
Study 7715474 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/day oral conjugated oestrogens (CEE) for 24 months
Number of subjects: 68
Study 7715474 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (control) for 24 months
Number of subjects: 68
Study 3503665 — intervention group
Group type: EXPERIMENTAL
Intervention: High tones (target tones)
Number of subjects: 0
Study 3503665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontarget tones
Number of subjects: 0
Study 3503665 — intervention group
Group type: EXPERIMENTAL
Intervention: Target tones
Number of subjects: 0
Study 3503665 — intervention group
Group type: EXPERIMENTAL
Intervention: Preceding sequence of tones
Number of subjects: 0
Study 31038645 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative material on organ donation
Number of subjects: 739
Study 31038645 — intervention group
Group type: COMPARATOR
Intervention: Control group (no informative material)
Number of subjects: 739
Study 29589480 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive range of motion in ankle dorsiflexion with flexed and extended knee
Number of subjects: 60
Study 29589480 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait Variable Score of the ankle
Number of subjects: 60
Study 29589480 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak dorsiflexion during gait
Number of subjects: 60
Study 27442662 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency thermocoagulation at 75°C
Number of subjects: 62
Study 27442662 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency thermocoagulation at 68°C
Number of subjects: 62
Study 23478748 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 PUFA supplementation (1.2 g per day)
Number of subjects: 81
Study 23478748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 23478748 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 PUFA supplementation
Number of subjects: 81
Study 22614774 — intervention group
Group type: EXPERIMENTAL
Intervention: Laninamivir octanoate (LO) 20 or 40 mg (depending on age), single inhalation
Number of subjects: 112
Study 22614774 — intervention group
Group type: COMPARATOR
Intervention: Zanamivir (ZN) 20 mg, inhaled twice daily for 5 days
Number of subjects: 112
Study 22614774 — intervention group
Group type: EXPERIMENTAL
Intervention: Laninamivir octanoate (LO)
Number of subjects: 112
Study 22614774 — intervention group
Group type: COMPARATOR
Intervention: Zanamivir (ZN)
Number of subjects: 112
Study 19610037 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal therapy treatment (PT)
Number of subjects: 32
Study 19610037 — intervention group
Group type: COMPARATOR
Intervention: Topical antibiotic treatment (C)
Number of subjects: 32
Study 19610037 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PT group vs C group
Number of subjects: 32
Study 19610037 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal preparations
Number of subjects: 32
Study 19064472 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention (four 2‐hour manualized educational/support group meetings; n = 31)
Number of subjects: 66
Study 19064472 — intervention group
Group type: COMPARATOR
Intervention: Written materials only (n = 23)
Number of subjects: 66
Study 19064472 — intervention group
Group type: COMPARATOR
Intervention: Control (written materials after a posttest; n = 12)
Number of subjects: 66